Video
Dr. Martin on Trial of Oral Azacitidine Plus R-CHOP in High Risk DLBCL
Author(s):
Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses a trial of the combination of oral azacitidine (CC-486) and R-CHOP in diffuse large B-cell lymphoma (DLBCL).
Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses a trial of the combination of oral azacitidine (CC-486) and R-CHOP in diffuse large B-cell lymphoma (DLBCL).
This was a phase I, open-label, multicenter trial of oral azacitidine plus R-CHOP in patients with high-risk, previously untreated DLBCL, grade 3B follicular lymphoma, or transformed lymphoma.
Martin says that 30% to 40% of patients with DLBCL cannot be cured with standard R-CHOP chemotherapy, making this combination a viable option.
